文献速递消化系统肿瘤

胰腺癌:将肿瘤生物学转化为可干预靶点

Pancreatic Cancer: Translating Tumor Biology into Actionability.
PubMed 文献 · Cancer Discov · 2026-01-01

化疗是所有分期的基石,靶向治疗适用于部分可干预基因组变异患者,肿瘤微环境致密间质与免疫抑制介导内在耐药。本文综述当前管理及靶向与免疫调节新范式。

要点

  • 化疗仍是所有分期基石,靶向治疗覆盖部分可干预基因组变异。
  • 致密间质与免疫抑制微环境是PDAC内在治疗抵抗的关键。

核心结论

  • 对PDAC病理生物学的新认识正转化为靶向与免疫调节治疗,有望改变治疗范式并改善这一难治性肿瘤的结局。

研究设计与样本

  • 本文为综述,围绕PDAC当前管理及新兴治疗范式(含靶向与免疫调节药物)进行汇总。

主要发现

  • 化疗是所有分期PDAC的基石。
  • 靶向治疗适用于携带部分可干预基因组变异且该范围在扩大的患者。
  • 肿瘤微环境提供致密间质与免疫抑制 milieu,参与PDAC的内在治疗抵抗。

临床怎么用

  • 各分期PDAC均应以化疗为基石进行管理。
  • 对携带可干预基因组变异的患者应考虑靶向治疗。
  • 认识间质与免疫抑制微环境有助于理解内在耐药并关注免疫调节策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Pancreatic ductal adenocarcinoma (PDAC) accounts for 90% of pancreatic cancers and has a very poor prognosis. Ten to 15% are staged as resectable at diagnosis, and 5% to 15% downstaged with therapy to where surgery is feasible. Chemotherapy is a mainstay for all stages of PDAC. Targeted therapies are available for patients with select but expanding actionable genomic alterations. The tumor microenvironment provides a dense stroma with an immunosuppressive milieu that contributes to inherent treatment resistance of PDAC. Herein, we review current management of PDAC with a focus on emerging treatment paradigms, including targeted and immunomodulatory agents. SIGNIFICANCE: PDAC is a complex disease with unique genomic, immunologic, and clinical features. Recent developments in understanding of the pathobiology of this disease are translating into targeted and immunomodulatory therapies that will alter treatment paradigms and improve outcomes for this recalcitrant malignancy.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Balogun FO, Sherman MH, Park W, et al. Pancreatic Cancer: Translating Tumor Biology into Actionability. Cancer Discov. 2026. PMID: 42381464. doi:10.1158/2159-8290.CD-25-2014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。